Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
Peking Union Medical College Hospital, Beijing, China
M D Anderson Cancer Center, Houston, Texas, United States
East Kent Hospital, Canterbury, United Kingdom
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Velindre Hospital, Cardiff, United Kingdom
Peking Union Medical College Hospital, Beijing, Beijing, China
Universitätsklinikum Mannheim GmbH, Frauenklinik, Mannheim, Baden-Württemberg, Germany
Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg, Hamburg, Germany
Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Germany
Research Site, Hochiminh, Vietnam
CHI Health Saint Francis, Grand Island, Nebraska, United States
CHI Health Good Samaritan, Kearney, Nebraska, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Kingman Regional Medical Center, Kingman, Arizona, United States
Cancer Hematology Centers - Flint, Flint, Michigan, United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.